sponsored content December 16, 2024 Privately held, clinical-stage pharmaceutical company, Sydnexis Inc. has recently completed an evaluation of its patented low-dose atropine...
July 16, 2024 DEL MAR, Calif. — Sydnexis has officially named a new Chief Executive Officer and member of the Board of...
sponsored content March 1, 2024 The evidence supporting the use of topical low-dose atropine in treating juvenile-onset myopia is so strong that...
January 19, 2024 SAN DIEGO — Sydnexis announced that Erin Horn has been named the Vice President, Head of Market Access at...
SAN DIEGO — Sydnexis Inc., a clinical stage biopharmaceutical company focused on the treatment of progressive myopia in children and minimizing the...
sponsored content August 15, 2023 Myopia is the most common eye disease in children and has experienced a dramatic increase in prevalence...
August 10, 2021 SAN DIEGO, Calif. — Sydnexis announced that it secured $45 million in Series B Financing, which was led by...
April 30, 2021 The Ophthalmology Innovation Summit (OIS) hosted a virtual Myopia Innovation Showcase on Thursday, April 29. The session started with...
April 12, 2021 CLICK HERE to view the presentation after April 29, 2021. The Ophthalmology Innovation Summit (OIS) will host a virtual...
November 1, 2020 By Thomas Aller, OD, FBCLA Collaborator, BHVI With the increasing incidence of myopia all around the world, predictions of...
Tens of millions of myopic children around the world need our help.
Jobson Medical Information will be the official North American media sponsor.
Jobson Optical Research, sponsored by Essilor, polled more than 300 optometrists in the U.S.